Opinion: PARP inhibitors in cancer-what do we still need to know?
Date
2022-07-01Author
Wicks, AJ
Krastev, DB
Pettitt, SJ
Tutt, ANJ
Lord, CJ
Type
Journal Article
Metadata
Show full item recordAbstract
PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We discuss the need to refine the current repertoire of clinical-grade companion biomarkers to be used with PARPi, so that patient stratification can be improved, the early emergence of drug resistance can be detected and dose-limiting toxicity can be predicted. We also highlight current thoughts about how PARPi resistance might be treated.
Collections
Subject
PARP inhibitors
biomarkers
cancer
drug resistance
synthetic lethality
Drug Resistance, Neoplasm
Humans
Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Research team
Gene Function
Language
eng
Date accepted
2022-07-01
License start date
2022-07-01
Citation
Open Biology, 2022, 12 (7), pp. 220118 -
Publisher
The Royal Society